Investigational drug · Phase 3
OPN-375
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Rhinosinusitis Without Nasal Polyps, Bilateral Nasal Polyposis.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
8
Any phase or sponsor naming "OPN-375"
First trial start
2018
Dec 31, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OPN-375", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Rhinosinusitis Without Nasal Polyps
- Bilateral Nasal Polyposis
Largest trials
Live from ClinicalTrials.gov: studies naming "OPN-375" as an intervention, largest first.
- Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal PolypsPivotal-lookingCompleted
Optinose US Inc.Industry
NCT03781804 · 332 participants · Start Nov 27, 2018 · Primary completion Jan 19, 2022
Drug: OPN-375 · For: Chronic Rhinosinusitis
Sites: Gilbert, Arizona; Bakersfield, California; Folsom, California · 92 sites in all
- Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional DevicePivotal-lookingCompleted
Optinose US Inc.Industry
NCT01624662 · 323 participants · Start Oct 30, 2013 · Primary completion May 11, 2015
Drug: Fluticasone propionate · For: Bilateral Nasal Polyposis
Sites: Stockton, California; Centennial, Colorado; Louisville, Kentucky · 10 sites in all
Optinose US Inc.Industry
NCT01622569 · 323 participants · Start Nov 19, 2013 · Primary completion Aug 6, 2015
Drug: Fluticasone Propionate · For: Bilateral Nasal Polyposis
Sites: Tucson, Arizona; Bakersfield, California; Fresno, California · 33 sites in all
- Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal PolypsPivotal-lookingCompleted
Optinose US Inc.Industry
NCT03960580 · 223 participants · Start Jun 6, 2019 · Primary completion May 4, 2022
Drug: OPN-375 · For: Chronic Rhinosinusitis
Sites: Birmingham, Alabama; Folsom, California; La Mesa, California · 87 sites in all
- 12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose DevicePivotal-lookingCompleted
Optinose US Inc.Industry
NCT01623310 · 223 participants · Start Sep 2013 · Primary completion Aug 2015
Drug: Fluticasone Propionate · For: Nasal Polyps
Sites: Birmingham, Alabama; Brandon, Florida; Normal, Illinois · 16 sites in all
- Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal PolypsPivotal-lookingRecruiting
Optinose US Inc.Industry
NCT06850805 · 84 participants (planned) · Start Jul 28, 2025 · Primary completion Mar 31, 2028
Drug: OPN-375; Placebo · For: Chronic Rhinosinusitis Without Nasal Polyps
Sites: Huntsville, Alabama; Gilbert, Arizona; Los Angeles, California · 24 sites in all
- OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal PolypsPivotal-lookingCompleted
Optinose US Inc.Industry
NCT03747458 · 40 participants · Start Dec 31, 2018 · Primary completion Mar 31, 2026
Drug: OPN-375 · For: Bilateral Nasal Polyposis
Sites: Gilbert, Arizona; Bakersfield, California; Fresno, California · 31 sites in all
- Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic VideoPivotal-lookingCompleted
Optinose US Inc.Industry
NCT03591068 · 11 participants · Start Jun 7, 2018 · Primary completion Feb 22, 2019
Drug: Fluticasone Propionate · For: Nasal Polyposis
Sites: Aurora, Colorado; Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy of Exhalation Delivery System With Fluticasone in Chronic Rhinosinusitis With Versus Without Polyps.
Schlosser RJ, Adappa ND, Chandra RK, et al. · Otolaryngol Head Neck Surg 2026
Also in development for Chronic Rhinosinusitis Without Nasal Polyps
- ItepekimabREGN3500, SAR440340Phase 39 trials
Sanofi · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.